COMMUNIQUÉS West-GlobeNewswire

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
06/01/2025
Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeks Overall, DNL343 was found to be safe and well tolerated [...]
HWH International Inc. Announces Closing of Approximately $1.76 Million Public Offering at $0.40 per Share
06/01/2025
BETHESDA, MD, Jan. 06, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the “Company”) (NASDAQ: HWH), a purpose-driven lifestyle company, today announced the closing of its public offering (the “Offering”) with [...]
ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment
06/01/2025
Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and [...]
Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company [...]
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06/01/2025
DUBLIN, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of [...]
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today [...]
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual [...]
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
06/01/2025
- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY ® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first [...]
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney
06/01/2025
Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA) MolDX confirms [...]
Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/01/2025
WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43 rd [...]
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
06/01/2025
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Conducted positive end [...]
MESA LABS DECLARES QUARTERLY DIVIDEND
06/01/2025
LAKEWOOD, Colo., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0 [...]
Bright Peak Therapeutics to Participate in 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
BASEL, Switzerland and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, [...]
SAFE - Assemblée générale mixte du 30 décembre 2024
06/01/2025
Assemblée générale mixte du 30 décembre 2024 Fleurieux-sur-l’Arbresle - France - le 6 janvier 2025 à 19h . L’assemblée générale des actionnaires de Safe réunie le 30 décembre 2024 à Fleurieux-sur-l’Arbresle, sous la [...]
UPDATE – LB Pharmaceuticals Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia, today [...]
Preliminary Financial Figures for the 2024 Fiscal Year
06/01/2025
January 6, 2025 Announcement no. 01 Preliminary Financial Figures for the 2024 Fiscal Year COPENHAGEN, DENMARK, January 6, 2025, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), an in [...]

Pages